Ladenburg Thalmann maintains NovoCure at Buy, raises price target to $31 from $27
Ladenburg Thalmann raised its price target for NovoCure to $31 from $27, maintaining a Buy rating. The new target suggests a 162.5% upside from the Nov 10 close of $11.81. Other recent analyst targets for NovoCure range from $15 to $20.
How this was made

The 30-second read
Why it matters
The upgrade may cause a short-lived rally but lacks a substantive catalyst.
Market read
Limited to investors tracking analyst opinions on biotech stocks.
What to watch
No new product or trial results were disclosed, so the upgrade rests on limited information.
Background
Analyst price target adjustments are routine and often reflect internal research rather than fresh market events.
Market effects
May slightly boost sentiment in the biotech/oncology sector.
Limited to US biotech investors.
Minimal global impact.
Counterpoint
The target raise could be premature without new clinical data; price may revert.
Key entities
- companyNovoCure
Biotech firm developing oncolytic immunotherapy.
- analystLadenburg Thalmann
Equity research firm issuing the price target.

